Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4886","jir_company_name":"Asuka Pharmaceutical Holdings Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-02-02","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/02\/4886-20260202-02.pdf","jir_short_summary":"Net sales of 54.4 billion yen, a 9.1% increase year-over-year. Operating income was 4.9 billion yen, a 10.6% decrease year-over-year. Full-year earnings guidance forecasts net sales of 71.0 billion yen and operating income of 6.0 billion yen.","jir_summary":"### Overview of Performance\nConsolidated net sales for the third quarter of the fiscal year ending March 2026 reached 54.4 billion yen, a 9.1% increase year-over-year, marking a record high. This was driven by steady performance in domestic operations and increased contributions from overseas business. Conversely, operating income was 4.9 billion yen, a 10.6% decrease year-over-year. The primary cause of profit decline was an increase in selling, general and administrative expenses, including research and development costs, which outpaced the increase in gross profit.\n\n### Segment Performance and Future Outlook\nThe prescription pharmaceuticals segment performed steadily, with growth driven by obstetrics and gynecology products 'Lelmina' and 'Droechi', as well as internal medicine products 'Thyroidine' and 'Refuxima'. The animal health segment also performed solidly, with sales up 1.0% year-over-year. The overseas business recorded sales of 324 million yen thanks to the contribution of newly consolidated subsidiary Hataphar. The full-year earnings guidance anticipates higher net sales of 71.0 billion yen and operating income of 6.0 billion yen, expecting both revenue and profit growth.","jir_financial_highlights":"Net Sales (Consolidated): 54.4 billion yen (9.1% increase YoY)\nCost of Goods Sold: 28.1 billion yen (Gross margin ratio increased by 0.7 points YoY)\nSelling, General and Administrative Expenses: 21.4 billion yen (SG&A to net sales ratio increased by 1.3 points YoY)\nOperating Income: 4.9 billion yen (10.6% decrease YoY)\nFull-year Net Sales Forecast: 71.0 billion yen (10.7% increase YoY)\nFull-year Operating Income Forecast: 6.0 billion yen (12.5% increase YoY)\nFull-year Net Income Attributable to Owners of Parent Forecast: 5.0 billion yen (2.0% decrease YoY)","jir_category":"","jir_hashtags":"#AsukaPharmaceuticalHoldings, #FinancialSummary, #JapaneseStocks","jir_key_figures":"Net Sales (Q3): 54.4 billion yen (9.1% increase YoY)\nOperating Income (Q3): 4.9 billion yen (10.6% decrease YoY)\nFull-year Net Sales Forecast: 71.0 billion yen (10.7% increase YoY)","jir_meta_title":"Asuka Pharmaceutical Holdings Q3 FY2026 Financial Summary: Net Sales 54.4 Billion Yen, Up 9.1%","jir_meta_description":"Supplementary materials for Asuka Pharmaceutical Holdings\u2019 Q3 FY2026 financial summary. Net sales reached 54.4 billion yen, up 9.1% year-over-year. Operating income was 4.9 billion yen, down 10.6%. Full-year forecasts anticipate net sales of 71.0 billion yen and operating income of 6.0 billion yen with growth in both revenue and profit.","jir_og_title":"Asuka Pharmaceutical Holdings FY2026 Q3 Financial Highlights","jir_og_description":"Net sales of 54.4 billion yen, up 9.1% year-over-year. Operating income was 4.9 billion yen, down 10.6%. Full-year results are expected to show revenue and profit growth.","jir_og_image_url":"\/assets\/og\/company-financial_summary.jpg","jir_chart_data_collection":"[{\"jir_chart_id\": \"revenue_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Net Sales Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2024\\\",\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Net Sales\\\",\\\"data\\\":[49926,49926,54486],\\\"borderColor\\\":\\\"#007bff\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"operating_profit_trend\", \"jir_chart_type\": \"line\", \"jir_chart_title\": \"Operating Income Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"line\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Q3 FY2024\\\",\\\"Q3 FY2025\\\",\\\"Q3 FY2026\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Operating Income\\\",\\\"data\\\":[5495,5495,4911],\\\"borderColor\\\":\\\"#dc3545\\\",\\\"fill\\\":false}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"segment_revenue_breakdown\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Segment Net Sales Breakdown (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Prescription Pharmaceuticals\\\",\\\"Animal Health\\\",\\\"Overseas Business\\\",\\\"Other Businesses\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2026\\\",\\\"data\\\":[45332,5759,3240,153],\\\"backgroundColor\\\":[\\\"#007bff\\\",\\\"#28a745\\\",\\\"#ffc107\\\",\\\"#6c757d\\\"]}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":false}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"major_product_sales\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Major Product Sales (Prescription Pharmaceuticals Segment)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"Thyroidine\\\",\\\"Candesartan Group\\\",\\\"Refuxima\\\",\\\"Mercazole\\\",\\\"Amlodipine\\\",\\\"Lelmina\\\",\\\"Droechi\\\",\\\"Frewell\\\",\\\"Luteum\\\",\\\"Ange\\\",\\\"Magvent\\\",\\\"Slinda\\\",\\\"Leuprorelin\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"Q3 FY2026 Results (Million Yen)\\\",\\\"data\\\":[6701,6148,5978,1263,619,8819,6353,2308,1751,463,538,242,2963],\\\"backgroundColor\\\":\\\"#007bff\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}, {\"jir_chart_id\": \"research_development_expense_trend\", \"jir_chart_type\": \"bar\", \"jir_chart_title\": \"Research and Development Expenses Trend (Million Yen)\", \"jir_chart_json_data\": \"{\\\"type\\\":\\\"bar\\\",\\\"data\\\":{\\\"labels\\\":[\\\"FY2024\\\",\\\"FY2025\\\",\\\"FY2026 (Forecast)\\\"],\\\"datasets\\\":[{\\\"label\\\":\\\"R&D Expenses\\\",\\\"data\\\":[4728,7031,6973],\\\"backgroundColor\\\":\\\"#17a2b8\\\"},{\\\"label\\\":\\\"Q3 Actual\\\",\\\"data\\\":[null,null,5405],\\\"backgroundColor\\\":\\\"#20c997\\\"}]},\\\"options\\\":{\\\"responsive\\\":true,\\\"plugins\\\":{\\\"legend\\\":{\\\"display\\\":true}},\\\"scales\\\":{\\\"y\\\":{\\\"beginAtZero\\\":true}}}}\"}]","ir_related_company":17164,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-23071","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n